Leuven, Belgium, Tuesday, December 13, 2022 – Last week CB Insights released the “Digital Health 150” 2022 list. We are proud to announce that ArtiQ was ranked among the 150 most promising digital health companies in the world. Only 8% of the companies making the list are European. ArtiQ is honored to be one of the 3 selected Belgian companies taking the lead in the Belgian and European healthcare innovation space.
ArtiQ was selected from a pool of over 13,000 companies, including both applicants and nominees. The selection was done based on various factors including, but not limited to, company business models and momentum in the market, funding, investor profiles, competitive positioning, tech novelty. CB Insights selected 150 top private companies transforming healthcare with digital innovation. The winning companies include startups working on, among others, clinical intelligence; digital therapeutics; screening, monitoring, & diagnostics; AR/VR in healthcare, hybrid care, …
It is an honor being named among the 8 most promising digital health tech companies active in Clinical Intelligence. As our CEO, PhD Marko Topalovic stated: “This is an extra motivational boost to succeed in our mission to empower medical professionals with artificial intelligence to diagnose, treat and follow-up patients with respiratory problems.”
About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights.
More information can be found at www.cbinsights.com
ArtiQ is a young, dynamic, and innovative spin-off company of the University of Leuven (Belgium). As a medical software company, ArtiQ is dedicated to improve how patients with respiratory complaints are diagnosed & monitored, and how pharmaceutical companies run & optimize respiratory clinical trials. ArtiQ builds and sells smart software to empower traditional respiratory devices and processes. Since 2019, together with researchers, clinicians, equipment manufacturers and pharmaceutical companies we aim to make key improvements for patients with lung diseases. More information can be found at www.artiq.eu